Home
HelpOrder Code CERAM MI-Heart Ceramides, Plasma
Useful For
Evaluating the risk of major adverse cardiovascular events within the next 1 to 5 years
Method Name
Liquid Chromatography Tandem Mass Spectrometry (LC-MS/MS)
Reporting Name
MI-Heart Ceramides, PSpecimen Type
Plasma EDTASpecimen Required
Patient Preparation: Patients should not be receiving Intralipid because it may cause false elevations in measured ceramides.
Collection Container/Tube: Lavender top (EDTA)
Submission Container/Tube: Plastic vial
Specimen Volume: 1 mL
Collection Instructions: Centrifuge, aliquot at least 1 mL of plasma into a plastic vial and freeze within 8 hours.
Specimen Minimum Volume
0.5 mL
Specimen Stability Information
| Specimen Type | Temperature | Time |
|---|---|---|
| Plasma EDTA | Frozen (preferred) | 30 days |
| Refrigerated | 24 hours | |
| Ambient | 8 hours |
Reject Due To
| Gross hemolysis | Reject |
| Gross lipemia | OK |
| Gross icterus | OK |
Reference Values
MI-Heart Ceramide Risk Score:
0-2 Lower risk
3-6 Moderate risk
7-9 Increased risk
10-12 Higher risk
Ceramide (16:0): 0.19-0.36 mcmol/L
Ceramide (18:0): 0.05-0.14 mcmol/L
Ceramide (24:1): 0.65-1.65 mcmol/L
Ceramide (16:0)/(24:0): <0.11
Ceramide (18:0)/(24:0): <0.05
Ceramide (24:1)/(24:0): <0.45
Reference values have not been established for patients who are less than 18 years of age.
Note: Ceramide (24:0) alone has not been independently associated with disease and will not be reported.
Method Description
Ceramides are separated and quantified by liquid chromatography tandem mass spectrometry (LC-MS/MS).(Unpublished Mayo method)
Day(s) Performed
Monday, Wednesday, Friday
Performing Laboratory
Mayo Clinic Laboratories in Rochester
CPT Code Information
0119U
Forms
If not ordering electronically, complete, print, and send a Cardiovascular Test Request Form (T724) with the specimen.